Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery. 

AZ/Merck & Co's Lynparza sets 'new standards' in ovarian can...

AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US cancer experts reviewing long-term trial data. 

AZ/Merck & Co's ovarian cancer drug gets wider US licence

AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

Epsilogen licenses first-in-class IgE ovarian cancer drug

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in